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Summary
BACKGROUND: Renal replacement therapy for paediatric
end-stage renal disease (ESRD) has developed steadily
since its introduction five decades ago. Continuous and
long-term analysis of patient outcomes is essential for
quality control.
METHODS: The Swiss Paediatric Renal Registry, founded
in 1970, includes patients diagnosed with ESRD, defined
as dialysis for more than three months or renal transplan-
tation, at age <20 years. Here we describe the incidence,
primary renal disease, treatment modalities and long-term
outcomes over 45 years.
RESULTS: This paper reports on 367 children and ado-
lescents treated with chronic renal replacement therapy
in Switzerland. Incidence was 5.4 per million children per
year, with a tendency to increase over time. The primary
renal disease was congenital anomalies of the kidney and
the urinary tract in 133 (36%), monogenetic hereditary dis-
eases in 122 (33%) and acquired diseases in 112 (31%)
patients. The first renal replacement therapy was
haemodialysis in 194 (53%), peritoneal dialysis in 116
(32%) and pre-emptive renal transplantation in 57 (15%)
patients. Over the years, pre-emptive renal transplantation
became more frequent (34% of all first renal replacement
therapies in 2006–2015), reducing the duration of dialysis.
Median time on dialysis until transplantation decreased
from 1.60 years in 1981–90 to 0.34 years in 2010–15.
Over the four decades 1970–80, 1981–90,1991–2000 and
2001–10, the one-year graft survival rate improved from
0.76 to 0.80, 0.89 and then 0.96; and the five-year graft
survival rate improved from 0.44 to 0.64, 0.84 and 0.89,
respectively. The five-year patient survival rates for the
four decades were 0.83, 0.99, 0.93 and 0.94; and the
10-year patient survival rates were 0.75, 0.96, 0.88 and
0.94, respectively. In the four cohorts starting renal re-
placement therapy in the 70s, 80s, 90s and 00s, the num-
ber of children alive after five years of renal replacement
therapy increased from 15 to 24, 47 and then 45 respec-
tively. In total, 29 patients (8%) died during chronic re-
nal replacement therapy with ESRD before the age of 20
years.
CONCLUSION: Over time, a higher number of children
on renal replacement therapy survived, graft survival im-
proved, and the duration of dialysis before renal transplan-
tation decreased.
Keywords: dialysis, renal transplantation, graft survival,
patient survival, end-stage renal disease, epidemiology
Introduction
Chronic kidney disease is a rare but severe condition in
childhood and adolescence, leading to end-stage renal dis-
ease (ESRD). Treatment – renal replacement therapy – in-
cludes haemodialysis, peritoneal dialysis and renal trans-
plantation from deceased or living donors. ESRD is
associated with high morbidity and mortality, including
cardiovascular complications, growth retardation, psy-
chosocial problems and impaired quality of life [1–6]. Re-
nal transplantation improves long-term outcome and qual-
ity of life [7, 8], but the necessary immunosuppressive
treatment leads to side effects, in particular infections and
malignancies [9, 10].
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National and international registries developed during re-
cent years describe the incidence, prevalence, underlying
primary disease, treatment modalities and complications in
children with ESRD [11–15]. This allows long-term out-
comes to be examined and comparisons between countries
to be made [13, 16–20]. However, registries use different
inclusion criteria and outcome parameters, and many start-
ed only recently. Longitudinal data describing time trends
in primary diseases, treatment modalities and survival are
rare [7, 21, 22].
The Swiss Paediatric Renal Registry (SPRR) was estab-
lished as a prospective cohort study in 1970, together with
the launch of paediatric renal replacement therapy in
Switzerland. In 1970, haemodialysis and renal transplanta-
tion were introduced in Switzerland, followed by continu-
ous ambulatory peritoneal dialysis. In 1995, renal replace-
ment therapy was introduced for children with syndromes
and variable cognitive impairment. Since 2009, data have
been regularly delivered to the European Society of Paedi-
atric Nephrology (ESPN) Registry. Previous SPRR publi-
cations have described the outcomes of 84 children treated
from 1970 to 1994 [21], of 48 patients transplanted from
1992 to 1999 [23] and of 51 children treated from 2001
to 2014, describing the effect of the Swiss Organ Allo-
cation System prioritising children and adolescents, intro-
duced by law in Switzerland in 2007 [24].
This publication gives a comprehensive overview of the
clinical epidemiology of ESRD in Switzerland during the
past 45 years (1970 – 2015). It describes (1) the incidence
of ESRD in children and adolescents, (2) the spectrum
of primary renal disease, (3) trends in different treatment
modalities (haemodialysis, peritoneal dialysis, renal trans-
plantation) and 4) long-term outcomes.
Methods
The Swiss Paediatric Renal Registry (SPRR)
The SPRR was built as a prospective cohort of all children
who develop ESRD before adulthood. Children and ado-
lescents newly diagnosed at one of the five Swiss pae-
diatric nephrology units (University Children's Hospitals
of Basel, Berne, Geneva, Lausanne and Zurich) were re-
ported to the registry. Inclusion criteria were dialysis for
more than three months and/or renal transplantation. Base-
line data at the start of renal replacement therapy were
complemented with annual follow-up data on treatment
changes, graft failure and cause of death. Appendix 1 gives
an overview of the data collected from 1970 to 2015. Eth-
ical approval was granted to the SPRR through the Ethics
Committee of the Canton of Bern (KEK-BE: 140/2015).
Statistical analysis
Incidence was calculated for the period 1981 to 2015 and
for the age group 0 to 14 years. For this group, complete-
ness of the incidence data was estimated at 95.5%. Incom-
plete patient inclusion was reported in the years before
1980 and in the age group 15 to 19 years, leading to the de-
cision to exclude this data from the incidence calculation.
The age-standardised annual incidence per million persons
was calculated using the official end-year Swiss resident
population as the denominator [25]. Patients living abroad
were excluded because they were not represented in the
reference population. The increase in incidence over time
was tested using a linear regression model. Differences in
incidence between boys and girls were examined using stu-
dent’s t-tests.
Primary renal disease and all other analyses except inci-
dence included all paediatric patients from the SPRR who
gave informed consent or (if applicable) assent. Primary
renal disease was categorised into congenital anomalies
of the kidney and urinary tract (CAKUT), monogenet-
ic hereditary diseases and acquired diseases. Primary re-
nal diseases were described by number, frequency within
the cohort, proportion of males diagnosed compared to
females, age at onset of renal replacement therapy (de-
scribed as mean and 95% confidence interval [CI]), and
incidence (described as mean and 95% CI, using the inci-
dence dataset).
First renal replacement therapy: For each decade
(1970–80, 1981–90, 1991–00, 2001–10, 2011–15), the
number of children treated with haemodialysis, peritoneal
dialysis and pre-emptive renal transplantation was tabulat-
ed for the different age groups (0–4, 5–9, 10–14, 15–19
years). The percentages of children undergoing pre-emp-
tive renal transplantation, haemodialysis and peritoneal
dialysis were shown over the last 10 years (2006–2015)
and over the whole study period by age group.
Duration of dialysis before first renal transplantation was
calculated for each child. Children were grouped into co-
horts depending on the decade in which renal replacement
therapy was started. For each cohort, dialysis duration was
displayed on a boxplot. The hypothesis that median wait-
ing time on dialysis became shorter was tested using
Mann-Whitney U-tests in which the most recent cohort
(2011–2015) was compared to the earlier ones.
Graft donors in renal transplantation 1970–2015: Number
of kidneys transplanted in Switzerland by type of graft
donor was displayed graphically, summarised for five-year
periods.
Graft and patient survival: Graft and patient survival were
computed using Kaplan-Meier curves from four cohorts,
i.e. children starting renal replacement therapy in 1970s,
1980s, 1990s and 2000s. Survival was compared between
the four cohorts using log-rank tests. Overall patient sur-
vival rates after 5, 10 and 15 years were described. Graft
and patient survival were censored at the end of the study
or when the patient was lost to follow-up.
Causes of death were assessed from the hospital records.
STATA, version 15.1 was used to analyse the data (Stata-
Corp. 2017. Stata Statistical Software: Release 15.1. Col-
lege Station, TX: StataCorp LP).
Results
Incidence
Between 1981 and 2015, 227 children under 15 years of
age started a chronic treatment for ESRD, the youngest
being three weeks old. The mean incidence was 5.4 chil-
dren per million children per year (per million person-
years; pmpy) and had a tendency to increase over time (p =
0.085). The increase in incidence over time was most no-
ticeable in children aged 0–4 years (in 1981–1984, inci-
dence was 0 pmpy; in 1985–2015, mean incidence was 5.4,
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ranging from 0–16.5 pmpy). Incidence was higher in boys
(6.3 pmpy) than in girls (4.5 pmpy, p = 0.009).
Primary renal disease
Out of all 367 children, 133 (36%) had CAKUT as the
primary disease, 122 (33%) had a hereditary disease and
112 (31%) had an acquired disease (table 1). The most fre-
quent diagnoses were obstructive uropathy with posteri-
or urethral valves (incidence: 1.0 pmpy), medullary cystic
disease including nephronophthisis (0.6 pmpy), congenital
renal dysplasia with or without urinary tract malformation
(0.6 pmpy) and congenital renal hypoplasia (0.4 pmpy).
Mean age at onset of ESRD was 10.4 years across the
whole study group. Onset of renal replacement therapy was
later in patients with reflux-associated nephropathy (age
13.8 years) and Henoch-Schoenlein nephropathy (12.5
years) and earlier in children with congenital nephrotic
syndrome (1.6 years) and atypical haemolytic uraemic syn-
drome (2.6 years, all p <0.0001). The remaining diagnoses
were Alport’s syndrome, Eagle-Barrett syndrome, congen-
ital nephrotic syndrome (Finnish type), Bardet-Biedl syn-
drome, Branchiootorenal syndrome, interstitial nephritis,
IgA nephropathy, renal vein thrombosis, proliferative
glomerulonephritis, systemic lupus erythematosus, Wilms
tumour / Denys-Drash syndrome, granulomatosis with
polyangiitis, diabetic nephropathy and anti-glomerular
basement membrane disease, each of which affected fewer
than five patients.
First renal replacement therapy
As first treatment, 194 (53%), 116 (32%) and 57 (15%)
children underwent haemodialysis, peritoneal dialysis and
pre-emptive renal transplantation respectively. Age at the
beginning of the first renal replacement therapy was 0–4
years for 70 (19%), 5–9 years for 78 (21%), 10–14 years
for 138 (38%) and 15–19 years for 81 (22%) patients. The
choice of starting therapy differed between age groups (p
<0.001). Children aged 0–4 years usually started renal re-
placement therapy with peritoneal dialysis, whereas old-
er children started primarily with haemodialysis. Table 2
shows the time trends of first renal replacement therapy
for different age groups. Pre-emptive renal transplantation
became more frequent over time (fig. 1). Between 2001
and 2010, 27% (n = 25) of all first renal transplantation
were pre-emptive, with 23 being living-related and only
two (8%) from deceased donors. Between 2011 and 2015,
41% (n = 15) of all first renal transplantation were pre-
emptive, with 11 (73%) originating from deceased donors.
Median waiting time on dialysis was shorter in the cohort
of 2011–15 compared with the cohorts starting renal re-
placement therapy before 2001 (all p <0.01), but was com-
parable with the cohort of 2001–2010 (p = 0.38, fig. 2).
For the five decades 1970–80, 81–90, 91–00, 2001–10
and 2011–15, median time on dialysis until transplantation
changed from 0.87 years (interquartile range [IQR]
1.79–0.49) to 1.60 years (IQR 2.57–0.52), 0.95 years (IQR
2.33–0.51), 0.58 years (IQR 1.44–0.00) and 0.34 years
(IQR 1.13–0.14), respectively.
Table 1: Primary renal diseases.
Primary renal disease All paediatric patients Males/ fe-
males
Age at start of RRT
(years)
Children
0–14 years*
Incidence pmpy
(age 0–14 years)*
n % Mean 95% CI n Mean 95% CI
All primary renal diseases 367 100 1.4 10.4 9.9–11.0 227 5.4 4.7–6.1
CAKUT 133 36.2 2.4 10.6 9.6–11.5 78 1.9 1.5–2.2
Renal hypoplasia 33 9 1.8 10.7 8.9–12.4 18 0.4 0.2–0.6
Congenital obstructive uropathy, posterior urethral valves† 32 8.7 n.a.† 9.4 7.2–11.6 21 1.0† 0.7–1.4
Congenital renal dysplasia with or without urinary tract malfor-
mation
36 9.8 2 9.5 7.4–11.5 25 0.6 0.4–0.8
Reflux-associated nephropathy 24 6.5 1.7 13.8 12.2–15.3 8 0.2 0.1–0.3
Oligomeganephronia hypoplasia 4 1.1 0.3 10.5 4.5–16.4 4 0.1 0.0–0.2
Other forms of CAKUT 4 1.1 0.3 11 0.0–20.0 2 0.0 0.0–0.1
Monogenetic hereditary diseases 122 33.2 1.3 10.5 9.5–11.5 85 2 1.6–2.5
Medullary cystic disease, including nephronophthisis 41 11.2 1 11.8 10.5–13.3 27 0.6 0.4–0.9
Cystinosis 17 4.6 1.1 11.3 9.8–12.9 13 0.3 0.1–0.5
Nephrotic syndrome (unspecified) 12 3.3 0.7 9 5.9–12.2 11 0.3 0.1–0.5
Nephrotic syndrome (DMS) 8 2.2 1 1.6 0.1–3.1 6 0.2 0.0–0.3
Nephrotic syndrome (FSGS) 6 1.6 2 10.4 3.9–17.0 5 0.1 0.0–0.2
Polycystic kidneys (autosomal recessive) 9 2.5 1.3 7.7 2.3–13.0 3 0.1 0.0–0.3
Primary hyperoxaluria type 1 8 2.2 1.7 11.2 5.8–16.6 8 0.1 0.0–0.2
Other monogenetic hereditary diseases 21 5.7 3.2 12.4 10.0–14.9 12 0.3 0.1–0.5
Acquired diseases 112 30.6 0.8 10.1 9.2–11.1 64 1.5 1.2–1.9
FSGS 33 9 0.8 11.4 10.1–12.7 14 0.3 0.1–0.5
Glomerulonephritis (unspecified) 16 4.4 1 10.6 8.4–12.7 7 0.2 0.0–0.3
Atypical haemolytic uraemic syndrome, (diarrhoea-negative) 12 3.3 0.7 2.6 0.7–4.4 11 0.3 0.1–0.4
Membranoproliferative glomerulonephritis 12 3.3 0.7 11.4 8.8–14.0 7 0.2 0.0–0.3
Cortical necrosis 8 2.2 0.1 9.6 3.0–16.2 3 0.1 0.0–0.2
Henoch-Schoenlein nephropathy 5 1.4 0.3 12.5 10.9–14.2 4 0.1 0.0–0.2
Other acquired diseases 26 7.1 1 10.8 8.7–12.9 18 0.4 0.2–0.6
CI = confidence interval; CAKUT = congenital anomalies of the kidney and urinary tract; DMS = diffuse mesangial sclerosis; FSGS = primary focal segmental glomerulosclerosis;
pmpy = per million population at risk per year; RRT = renal replacement therapy * Incidence was calculated using a subset of 227 children aged 0 to 14 years starting RRT in
1981–2015. † Congenital obstructive uropathy, posterior urethral valves concern only males. Male/female ratio is therefore not applicable (n.a.). Incidence was calculated using
population at risk: boys aged 0 to 14 years.
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Renal transplantation in children and adolescents
(1970–2015)
Overall, 322 (88%) children undergoing renal replacement
therapy were transplanted before the age of 20 years. A
second graft was transplanted in 43 (13%) and a third in
four patients (1%) during their time in paediatric care. Liv-
ing-related renal transplantation was introduced in 1986.
The cumulative number of renal transplantation per five
years increased from 1970 to 1985, but then plateaued in
1986 before peaking from 2006–2010 (i.e., the time period
after the change of the law favouring deceased donor or-
gan allocation to children had been implemented in 2007)
(fig. 3). Deceased donor organ donation increased steadily
up to 1985, then declined up to 2005. Since 2006 it has
Figure 1: First renal replacement therapy (RRT) in different
decades.
Figure 2: Duration of dialysis from start of first renal replacement
therapy (RRT) until transplantation in different decades.
increased again, whereas living-related donation has de-
creased markedly (fig. 3). Living donors were related to
the transplant receivers in 111 donations; five were non-re-
lated altruistic donors.
Graft survival
Graft survival at five years is displayed by decade using
Kaplan-Meier curves (fig. 4). Over the four decades
(1970s, 1980s, 1990s and 2000s), the one-year graft sur-
vival rate changed from 0.76 (95% CI 0.60–0.86) to 0.80
(0.68–0.88), 0.89 (0.81–0.94) and 0.97 (0.90–0.99), re-
spectively. The five-year graft survival rates in each decade
were 0.44 (95% CI 0.28–0.58), 0.64 (0.54–0.79), 0.84
(0.73–0.90) and 0.89 (0.73–0.90), respectively. The pair-
wise comparison of graft survival between decades showed
a gradual increase over time (70s versus 80s: p = 0.028;
80s versus 90s: p = 0.003; 90s versus 00s: p = 0.084).
Patient survival
The patient survival rates for the entire cohort were 0.92
(n = 214; 95% CI 0.88–0.95), 0.87 (n = 143; 95% CI
0.81–0.91) and 0.79 (n = 81; Cl 0.70–0.86) at 5, 10 and 15
years, respectively (fig. 5). The five-year patient survival
rates by ascending decade were 0.83 (95% CI 0.70–0.91),
0.99 (0.91–1.0), 0.93 (0.86–0.97) and 0.94 (0.86–0.97);
the 10-year patient survival rates were 0.75 (95% CI
0.61–0.85), 0.96 (0.87–0.99), 0.88 (0.79–0.94) and 0.94
(0.86–0.97) (fig. 5). The highest patient survival rate was
observed in the cohort starting renal replacement therapy
in 1981–1990, in an era when preschool children and chil-
dren with severe syndromic comorbidity had only limited
Figure 3: Number of transplanted grafts from deceased donors
and living donors in paediatric patients in different periods.
Table 2: Time trends of first renal replacement therapy in 367 children of different ages.
Age (years) 0 to 4
n = 70
5 to 9
n = 78
10 to 14
n = 138
15 to 19
n = 81
First RRT (n) HD PD RTPL HD PD RTPL HD PD RTPL HD PD RTPL
1970–1980 1 2 0 11 6 0 23 5 0 7 2 0
1981–1990 1 9 0 4 8 3 20 11 1 21 1 0
1991–2000 2 19 2 10 7 3 21 4 2 13 3 4
2001–2010 1 18 2 9 2 8 21 6 8 13 2 8
2011–2015 1 11 1 6 0 1 6 0 10 4 0 3
1970–2015 6 59 5 40 23 15 91 26 21 58 8 15
First RRT (%) HD PD RTPL HD PD RTPL HD PD RTPL HD PD RTPL
1970–2015 8.6 84.3 7.1 51.3 29.5 19.2 65.9 18.8 15.2 71.6 9.9 18.5
2006*–2015 4.0 84.0 12.0 66.7 0.0 33.3 48.4 12.9 38.7 62.5 4.2 33.3
HD = haemodialysis; PD = peritoneal dialysis; RTPL = renal transplantation; RRT = renal replacement therapy * 2007: Introduction of the Swiss organ allocation system
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access to chronic renal replacement therapy. Only 24 chil-
dren in this cohort survived five years on renal replacement
therapy, compared with 47 and 45 children in the 90s and
00s and with 15 children in the 70s. The pairwise compari-
son of patient survival between decades did not reveal sig-
nificant differences between the curves (70s versus 80s: p
= 0.20; 80s versus 90s: p = 0.79; 90s versus 00s: p = 0.74).
The survival rates of children aged 0–2 years at 1, 2, 5
and 10 years were 0.97, 0.95, 0.92 and 0.82 (95% CI
0.83–1.0, 0.81–0.99, 0.77–0.97 and 0.64–0.91), respective-
ly. The survival rates of children younger than two years
with chronic renal replacement therapy in the cohorts start-
ing renal replacement therapy in the 1990s and the 2000s
are comparable (p = 0.81). The survival rate in children
younger than two years with chronic renal replacement
therapy in the 1970s and 1980s was 1.0 at five years. In to-
tal, a higher number of children aged 0–2 years survived
five years with renal replacement therapy in the 1990s and
2000s (n = 20) than in the 1970s and 1980s (n = 8). In syn-
dromic children, the survival rate at five years was 1.0 be-
fore and after 1990. A higher number of syndromic chil-
dren survived five years with renal replacement therapy in
the 1990s and 2000s (n = 19) than in the 1970s and 1980s
(n = 6).
Causes of death
There were 48 deaths in 3546 years of follow-up, resulting
in 13.5 deaths per 1000 patient years. Twenty-nine (8%)
of the 367 patients recorded in the registry died before the
Figure 4: Renal transplantation (RTPL) graft survival displayed by
decade of transplantation using Kaplan-Meier curves.
Figure 5: Renal replacement therapy (RRT) patient survival dis-
played by decade of start of treatment using Kaplan-Meier curves.
age of 20 years. Of those, six died on haemodialysis (two
with vasculitis, two with multiorgan failure, one with hy-
pertensive cardiac failure and one with uraemia) and six
died on peritoneal dialysis (two with septicaemia, two with
multiorgan failure, one with hyperkalaemia and one with a
malignant solid tumour). There were 17 deaths after renal
transplantation (six with multi-organ failure, six with sep-
ticaemia, three with cardiac arrest and two with uraemia).
Discussion
From the very start of paediatric kidney transplantation in
Switzerland in 1970, paediatric nephrologists established
a national registry. This allows us today to summarise
long-term results from children undergoing renal replace-
ment therapy and to compare our data with other registries.
Time trends of incidence, primary renal disease, treatment
modalities and outcomes in 367 children are available over
a period of 45 years. Between 1981 and 2015, 227 children
aged 0–14 years were diagnosed with ESRD, resulting in
an incidence of 5.4 children pmpy. The UK reported a
higher incidence of 7.9 pmpy for children <16 years [26].
Comparing incidence with other European countries is dif-
ficult because inclusion criteria vary between studies [13].
In Sweden, incidence was reported at 7.7 pmpy, with 118
children diagnosed with chronic renal disease, defined as
a glomerular filtration rate (GFR) <30 ml/min per 1.73 m2
body surface in children aged 0.5 – 15 years [17]. The
ItalKid project reported an incidence of 12.1 pmpy, with
1197 patients aged 0–19 years with moderate to severe
chronic renal disease, defined as a GFR of <75 ml/min
per 1.73 m2 body surface. This project reported a lower
incidence of patients undergoing renal transplantation of
7.3/year/100 patients [18]. In other countries, incidence is
higher than in this study, but these rates include not only
patients undergoing renal transplantation, but also children
with impaired GFR [16, 19, 20]. It is thus not surpris-
ing that the incidence we report for Switzerland is low-
er, as we included only children with ESRD and chron-
ic renal replacement therapy. Similar to other reports [13],
we found that boys were more often affected than girls.
In the long observation period, we found a small increase
in the incidence of renal replacement therapy of 0.6 pmpy
over 10 years. This might be explained by improvements
in the intensive care of children with acute kidney injury
[27], resulting in higher numbers of children with more
complex renal disorders and multi-organ involvement, in-
cluding cognitive impairment in syndromic patients, on re-
nal replacement therapy, especially at a younger age (even
from the neonatal period) [22]. The calculation of inci-
dence by primary renal disease was based on very small
numbers. Some chance variation may explain differences
from findings in other countries.
Across the 45-year study period, the primary renal disease
leading to renal replacement therapy in Switzerland was
CAKUT in 36%, hereditary disease in 33% and acquired
disease in 31% of patients. Registries in the USA [28],
Italy [18], Belgium [20] and the United Kingdom [26] have
also found that CAKUT is the most common primary re-
nal disease resulting in ESRD. Registries from the ESPN
[29] and Australia [30] show incidences of CAKUT simi-
lar to our data. However, registries with a high proportion
(48–59%) of CAKUT refer to patients <20 years with
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chronic kidney disease (GFR <75 ml/min/1.73 m2) and not
to patients with ESRD [18, 20]. As the inclusion criteria of
the SPRR are similar to those of the ESPN and the Aus-
tralian registry, these results are comparable. Children and
adolescents with CAKUT have renal impairment, but ES-
RD and renal replacement therapy happen later in life. The
median age of patients undergoing renal replacement ther-
apy is 31 years [15].
Observation of treatment modality over such a long time
illustrates key developments in paediatric renal medicine
and the progress that has been achieved. We found an age-
related difference in the type of dialysis modality, espe-
cially during the first three decades. While haemodialysis
was the first treatment of choice in patients >five years of
age in the seventies, peritoneal dialysis became the pre-
ferred first-line treatment in under-fives later on, as the
technique and dialysis solutions developed and were adapt-
ed to younger patients [31]. Peritoneal dialysis is widely
considered to be the ideal first dialysis modality, especial-
ly in very young paediatric patients [32]. However, con-
sidering the whole period and including all age categories,
53% of all patients were initially treated with haemodialy-
sis, 32% with peritoneal dialysis and only 15% got a pre-
emptive renal transplant. These observations agree with
European data which found that 17% of patients are trans-
planted pre-emptively [33]. Considering that the benefit in
life expectancy of a pre-emptive renal transplantation com-
pared with chronic dialysis is about 20 years [34] and that
quality of life and long-term survival are superior in trans-
planted patients compared to those remaining on the wait-
ing list [35], this number seems far too low. In terms of de-
ceased donor organ donation, there is a wide disparity in
European countries regarding organ allocation [33]. Based
on a shortage of deceased donor organs in Switzerland, liv-
ing donation became popular during the nineties, steadily
increasing until 2006, but declining thereafter. This is be-
cause in 2007 an organ allocation system was introduced
by law in Switzerland. This new system prioritises all pa-
tients <20 years, leading to shorter waiting times and the
possibility of a pre-emptive deceased donor transplantation
without prior dialysis [25]. The total number of children
who were transplanted as first treatment grew consistently
over time in all age groups.
We observed a consistent improvement in graft survival
over time. This trend is explained by improved pre-trans-
plant preparation, better donor selection, more potent and
selective immunosuppression, optimised surgical tech-
niques, better postoperative management and the possibil-
ity of adequate antiviral prophylaxis [36]. We observed an
overall five-year graft survival of 72%. In other registries
graft survival varied enormously, between 44% and 95%
[37–42], depending on observation period, type of country
and the availability of renal transplantation in the paedi-
atric population. A Dutch study described a 10-year graft
survival rate of 45% in 397 renal transplantation performed
in 249 children [39]. For the same time period and a com-
parable patient cohort, the SPRR found a 10-year graft sur-
vival of 57% for Switzerland.
In terms of patient survival, in our study, 92%, 87% and
79% of the children survived the first 5, 10 and 15 years af-
ter diagnosis respectively. McDonald et al., in a long-term
survival study including 1634 children from 1963 to 2002,
also showed that patient survival steadily improved, but
was still worse for the youngest patients aged < five years
[7]. Twenty-nine of the 367 children in our cohort died.
Deaths were due to a variety of reasons, but cardiovascular
and infection-associated mortality were the most common
[14, 43, 44]. In adults, causes of death changed over time,
with cardiovascular mortality decreasing and infection-as-
sociated mortality increasing, the latter indicating side ef-
fects of more potent immunosuppression [45].
Notably, the economic status of a country remains the key
determinant of long-term outcome in children undergoing
renal replacement therapy [46]. In the majority of countries
there is still a lack of financial and human resources, re-
sulting in the inability to treat children with ESRD [47].
The strength of the SPRR is the high completeness of its
data for all children aged 0 to 14 years treated with renal
replacement therapy for chronic ESRD after 1980 and res-
ident in Switzerland. Although the small size of the co-
hort does not allow short-term developments to be studied,
the SPPR contributes to international collaborations, espe-
cially to the ESPN registry. Existing for nearly 50 years,
the cohort is a rich resource for analysing long-term de-
velopments. A limitation is the lack of clinical follow-up
data after transition. However, we plan to link the registry
with the adult renal registry in our country. In summary,
over time, a higher number of children on renal replace-
ment therapy survived, graft survival improved, and dialy-
sis duration before renal transplantation decreased.
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Appendix 1 Overview of the data collected from 1970 to
2015
The appendix is available as a separate file at
https://smw.ch/article/doi/smw.2020.20300.
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